AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00862745 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fesoterodine
Description: Participants will be instructed to take one tablet of blinded study medication once a day, orally, for 12 weeks. They will start with a 4 mg dose of study medication and will have the option of doubling that dose after 2 or 4 weeks if they wish. At the end of the 12 week blinded trial, participants will be offered open-label fesoterodine (Toviaz™), for 9 months beginning at 4 mg with participant directed dose adjustment.
Study NCT00862745 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo
Description: Participants will be instructed to take one tablet of blinded study medication once a day, orally, for 12 weeks. They will start with a 4 mg dose of study medication and will have the option of doubling that dose after 2 or 4 weeks if they wish. At the end of the 12 week blinded trial, participants will be offered open-label fesoterodine (Toviaz™), for 9 months beginning at 4 mg with participant directed dose adjustment.
Study NCT03584022 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biopsy + Nerve Repair
Description: During the standard sural nerve biopsy procedure, a single-use, biodegradable implant designed to repair damaged peripheral nerves will be used to repair the nerve. The MCNS1 is a hollow nerve tube made of poly(caprolactone-fumarate) (PCLF), to connect severed nerve ends and promote the growth of regenerating axons.
Study NCT03584022 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Biopsy Only
Description: Standard sural nerve biopsy only, without nerve repair.
Study NCT01318304 — intervention group
Intervention type: OTHER
Intervention: Vaginal lavage specimen
Description: Collection of 3cc of saline used in the vagina to collect innate immunity markers
Study NCT01516814 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (Xarelto, BAY59-7939)
Description: 15 mg twice daily for 21 days, followed by 15 mg once daily
Study NCT01516814 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Unfractionated heparin
Description: To be adjusted to maintain the activated partial thromboplastin time (aPTT) prolongation (1.5 to 2.5 times the control)
Study NCT01516814 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Warfarin
Description: To be adjusted on the basis of prothrombin time-international normalized ratio (PT-INR) values target range (1.5 to 2.5)
Study NCT03209583 — intervention group
Intervention type: DEVICE
Intervention: Medtronic
Description: Pacing is done by the implanted device after seeing how the electrical system is functioning giving energy when needed to maintain a stable state or rhythm
Study NCT03299946 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Description: Cabozantinib (40mg) will be taken by mouth daily for 8 weeks.
Study NCT02058576 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Commercially available combination of dutasteride 0.5 mg and tamsulosin HCL 0.4 mg
Description: Commercially available, orange and brown, hard shell capsule, administered orally as a single dose on Day 1 under fed condition.
Study NCT02058576 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Second generation dutasteride 0.5 mg and tamsulosin HCL 0.4 mg combination capsule
Description: Orange and brown, hard shell capsule, administered orally, as a single-dose on Day 1 under fed condition
Study NCT04294472 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MAU868
Description: MAU868 is a human monoclonal antibody (IgG1) that binds the viral capsid protein, VP1, that is responsible for binding to the surface of host cells
Study NCT04294472 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 250 mL D5W placebo IV to be labeled to match that of MAU868
Study NCT00110149 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Study NCT00110149 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: yttrium Y 90 ibritumomab tiuxetan
Study NCT03336853 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HybenX
Description: The material was introduced inside the root canal using the pre-dosed syringe for 20 seconds with a sterile paper point with and up and down movement up to the working length.~Finally, the canal was rinsed with sterile water using a syringe with a side-vented 30 G needle 1 mm shorter than the working length.~A second sterile paper point was introduced in the root canal, up to the working length, for 10 seconds to detect the presence of blood and the millimeters of blood inside the root canal was measured again according the previous criteria.
Study NCT03336853 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo control
Description: The root canal was irrigated with sterile saline water with a syringe and a side-vented 30G needle activated for 20 seconds with a sterile paper point with and up and down movement up to the working length to ensure a flow of irrigant solution throughout the canal.~Finally, the canal was rinsed with sterile water using a syringe with a side-vented 30 G needle 1 mm shorter than the working length. A second sterile paper point was introduced in the root canal, up to the working length, for 10 seconds to detect the presence of blood and the millimeters of blood inside the root canal was measured again according the previous criteria.
Study NCT00811538 — intervention group
Intervention type: PROCEDURE
Intervention: Intravenous Thrombolysis
Description: i.V. thrombolysis with rtPa
Study NCT00811538 — intervention group
Intervention type: PROCEDURE
Intervention: Intraarterial Thrombolysis
Description: Endovascular treatment with i.a. Urokinase or i.a. rtPA or mechanical recanalization techniques
Study NCT02678260 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PDR001
Description: PDR001 is a high-affinity, ligand-blocking, humanized anti-PD-1 IgG4 antibody that blocks the binding of PD-L1 and PD-L2 to PD-1.
Study NCT03479606 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online Emotion Regulation Skills-training
Description: Emotion Regulation Training (EmReg) is a cognitive-behavioral approach which aims to increase awareness, and self-monitoring of affective states to improve self-regulation. The intervention is divided into two phases: knowledge provision and practice facilitation. During the knowledge provision phase participants are introduced to the objectives and the main concepts of the intervention, to increase their familiarity with the terminology, and to the emotion regulation skills they acquire during the practice facilitation phase. During the practice facilitation phase participants receive training in emotion regulation skills, which they practice in-session with the guidance of the therapist and feedback from the group, as well as out-of-session as homework assignments.
Study NCT03479606 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Online Emotion Regulation Skills-training
Description: Emotion Regulation Training (EmReg) is a cognitive-behavioral approach which aims to increase awareness, and self-monitoring of affective states to improve self-regulation. The intervention is divided into two phases: knowledge provision and practice facilitation. During the knowledge provision phase participants are introduced to the objectives and the main concepts of the intervention, to increase their familiarity with the terminology, and to the emotion regulation skills they acquire during the practice facilitation phase. During the practice facilitation phase participants receive training in emotion regulation skills, which they practice in-session with the guidance of the therapist and feedback from the group, as well as out-of-session as homework assignments.
Study NCT01621620 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Yohimbine
Study NCT00363922 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Rehabilitation in institution
Description: Rehabilitation in institution for four weeks. Subjects follow standard rehabilitation in the center.
Study NCT00363922 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Rehabilitation at home
Description: Subjects get a written prescription of exercise training, diet, etc. to follow at home.
Study NCT00363922 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Out-patient rehabilitation at the hospital
Description: This intervention was removed. We never got time to randomize subjects into this category. We had planned to randomize patients from one hospital to either Rehabilitation in institution (rehab center) or rehabilitation at the hospital (out patient). And also patients from another hospital to either rehabilitation in institution (rehab centre) or rehabilitation at home. We have only managed to start the study in this second hospital so far (due to maternity leave and limited time to finish a PhD)
Study NCT06208228 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Kinesiotaping
Description: Kinesiotape application to masseter and hyoid muscles of late preterm infants for improving sucking and swallowing.
Study NCT02604108 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Exercise
Description: The Physical Exercise arm includes a training workshop and electronic health messages related to positive psychology and physical activity for all participants in physical exercise group. Skills on program design and implementation will be conducted for those participants, who will design and implement community-based family intervention to the public.~The training workshop includes: (i) 2-day core session and half day booster session for trainers; and (ii) 1-day core session and half day booster session for ambassadors
Study NCT02604108 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Diet
Description: The Healthy Diet arm includes a training workshop and electronic health messages related to positive psychology and health diet for all participants in healthy diet group. Skills on program design and implementation will be conducted for those participants, who will design and implement community-based family intervention to the public.~The training workshop includes: (i) 2-day core session and half day booster session for trainers; and (ii) 1-day core session and half day booster session for ambassadors
Study NCT00740701 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Cerebellar transcranial magnetic stimulation
Description: single pulse TMS or repetitive TMS at 1 Hz frequency
Study NCT00740701 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cerebellar transcranial magnetic stimulation
Description: single pulse TMS or repetitive TMS at 1 Hz frequency
Study NCT03706781 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetylpyridinium Chloride 0.05% + Benzydamine HCl 0.15% + mucus adhesive polymer
Description: Test product will be applied twice a day (b.i.d) every 12 h once in the morning and once in the evening for 6 consecutive days (from Day 1 to Day 6) and once in the morning on Day 7 for a total of 13 dose
Study NCT03706781 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetylpyridinium Chloride 0.05% + Benzydamine HCl 0.15%
Description: Reference Product will be applied twice a day (b.i.d) every 12 h once in the morning and once in the evening for 6 consecutive days (from Day 1 to Day 6) and once in the morning on Day 7 for a total of 13 dose
Study NCT01569490 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Incentives for abstinence and treatment engagement
Description: Treatment Incentives - incentives for biochemical verification visits, treatment engagement, and abstinence
Study NCT01569490 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Attendance incentive
Description: Attendance Incentives - incentives for only attending the biochemical verification visits
Study NCT03033511 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for dexamethasone
Description: Placebo for dexamethasone PO twice daily on Day -1, Day 1 (the day of dosing), and Day 2 of each 6 week cycle, omitting every third cycle.
Study NCT03033511 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for rovalpituzumab tesirine
Description: Placebo for rovalpituzumab tesirine administered intravenously Day 1 of each 6-week cycle, omitting every third cycle
Study NCT03033511 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rovalpituzumab tesirine
Description: Rovalpituzumab tesirine 0.3 mg/kg administered intravenously Day 1 of each 6-week cycle, omitting every third cycle
Study NCT03033511 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone 8 mg administered orally (PO) twice daily on Day -1, Day 1 (the day of dosing), and Day 2 of each 6 week cycle, omitting every third cycle.
Study NCT04044716 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Auricular acupressure
Description: Trained nurses in auricular acupressure will place acupressure beads on 5 acupoints on each ear (cingulate gyrus, thalamus, omega-2, point zero, and Shen Men). The nurse will do the initial activation of the acupressure site by applying pressure for 30 seconds to each point until the participant reports tingling or moderate degree of pressure. Participant will be given instructions to do this three times a day for a total of 5 days. Acupoints were selected based on recommendation of faculty acupuncturist.
Study NCT04044716 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of care pain management
Description: The participant post-operative pain will be managed following the standard protocol by the treating physician.
Study NCT04044716 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care pain management
Description: The participant post-operative pain will be managed following the standard protocol by the treating physician.
Study NCT01981863 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epsilonaminocaproic acid
Description: One group receives Epsilonaminocaproic acid, 10 gr IV bolus, followed by 1 gr/hr. Second group receives placebo.
Study NCT01981863 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered in same volume as in experimental arm.
Study NCT01338480 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: video
Description: The videos will be developed and contain information on the procedure, risks, benefits, and alternatives of the surgery. The knowledge measure instrument will also be developed.
Study NCT01145352 — intervention group
Intervention type: DRUG
Intervention: Etanercept (genetical recombination)
Description: All patients who administrated ENBREL for active polyarticular juvenile idiopathic arthritis (restricted to the case of lack of effect by other treatment) during registered period (2.5 year).
Study NCT00000273 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: opiates
Description: prescription opioids
Study NCT02383420 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: Live subjects will receive two x-rays, one with predicate detector and one using the GOS or CsI investigational detector. Multiple exams (head, chest, legs, etc) were made on the cadavers. Each exam area received one x-ray using the predicate detector and two x-rays using both the GoS and the CsI investigational detector.
Study NCT04734522 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Progressive Additional Lenses (PAL), pre calibrated and made of polymeric material with anti-reflection coating
Description: Subjects will be wearing three different PAL designs with different geometries of the optical progression.
Study NCT04734522 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Progressive Additional Lenses (PAL), pre calibrated and made of polymeric material with anti-reflection coating
Description: Subjects will be wearing three different PAL designs with different geometries of the optical progression.
Study NCT05802082 — intervention group
Intervention type: OTHER
Intervention: The Modified Yale Preoperative Anxiety Scale (m-YPAS) of children
Description: Postoperative 0,5,10,15,30,45,60.and 120 minutes , PAED and WBYAS values
Study NCT02389010 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogeneic cord blood platelet gel-CBPG
Description: For the medication of patients, one CBPG unit (mean volume 10 mL, range 5-15; mean platelet concentration 1 x 109/L, range 0.8 - 1.2 x 109/L. 10 mL in plasma) will be administered every 3-4 days. CBPG units, cryopreserved and stored in a plastic bag in a -80°C freezer, will be thawed at 37°C in a waterbath and activated with Calcium gluconate and immediately transported to sites of clinical use and applied to the skin ulcer without breaking the sterility chain.
Study NCT02389010 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Local Medications-SLM
Description: Each clinical center will use their validated standard local medications. Details and specifications of the local standard medication procedures will be collected from each participating centre.
Study NCT01435954 — intervention group
Intervention type: DRUG
Intervention: Early combination therapy
Description: If index drug was an alpha-blocker (AB) (alfuzosin, doxazosin, tamsulosin, or terazosin), a pharmacy claims for a 5-alpha reductase inhibitor (5ARI) (dutasteride, finasteride) on or within 30 days after the index date or if index drug was 5ARI, fill for an AB on or within 30 days after the index date
Study NCT01241526 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Disease Management
Description: * Individual, group and phone education sessions~* Telephone supporter follow-up~* LTOT monitoring
Study NCT01241526 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual site management
Description: * Usual education as per site protocol~* Usual follow-up as per site protocol~* LTOT monitoring
Study NCT03393390 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Clinical Assessment Visit
Description: Subjects will meet with a clinician who will determine if they meet diagnostic criteria for an externalizing disorder.
Study NCT01435954 — intervention group
Intervention type: DRUG
Intervention: Delayed combination therapy
Description: If index drug was an AB (alfuzosin, doxazosin, tamsulosin, or terazosin), a pharmacy claim for a 5ARI (dutasteride, finasteride) more than 30 days but less than or equal to 180 days of the index date
Study NCT03393390 — intervention group
Intervention type: OTHER
Intervention: fMRI scan
Description: Subjects will undergo an fMRI scan where images will be taken for observational purposes only, not as a means of diagnosis.
Study NCT01939509 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atenolol
Description: Crossover (atenolol 25-50 mg, bisoprolol 2.5-5 mg)
Study NCT01939509 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bisoprolol
Study NCT03877783 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: mediterranean diet
Description: The recommended Mediterranean diet is based on lean meat, fish, eggs, vegetables, fruits, berries, and nuts. Extra-virgin olive oil is the recommended additional fat source for use in food preparation and dressings. Recommended exclusions or restrictions include dairy products, cereals, added salt, refined fats, and sugar. Participants in the intervention group will receive weekly deliveries of olive oil and mixed nuts, free of cost, and they will receive recipes for Mediterranean meals on a regular basis. During the study, the intervention group will receive written, personalized advice from a project dietician on how to improve their Mediterranean diets. This written personalized advice will be based on the reported food intake, its coherence with a Mediterranean diet, and its adherence to the recommended intakes of energy and nutrients for each participant.
Study NCT03877783 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: individualized fitness program
Description: The exercise intervention will consist of individualized training programs designed to improve cardiovascular fitness (VO2). A personal trainer will distribute the training program instructions and monitor the training during the entire intervention. Support will be provided via text messages. The training intensity will be based on results from an extensive pre-test of individual physical fitness performance, and we will adjust the intensity over the study period, as fitness improves. The goal is to engage participants in training three times per week, for up to one hour per training session. The individualized training programs will consist of brisk walks, jogging, and cycling, tailored to each participant. To ensure that the training intensity is sufficient to improve cardiovascular fitness, heart rate will be monitored during each session.
Study NCT04588012 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The online self-help Program OurRelationship developed by prof. Brian Doss and prof. Andrew Christensen.
Description: The OurRelationship program is developed by prof. Brian Doss and prof. Andrew Christensen.
Study NCT04588012 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: The off line self-help course Pas på Parforholdet.
Description: The book Pas på parforholdet is written by Mattias Stølen Due.
Study NCT03877783 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: recommended modified pharmacological treatment
Description: Hyperglycemia: first metformin till target level of HbA1c 1) 53-58 mmol/mol for patients with ≤2 coexisting chronic illnesses or 2) 59-64 mmol/mol for those with established cardiovascular disease (CVD). We will recommend a second glucose-lowering drug when HbA1c is not achieved and which reduce CVD even when the participant does not have a manifest CVD.~Hypertension: will be treated to achieve a target level according to European guidelines. Start with a combination of a renin-angiotensin system (RAS)-blocker and a thiazide in low dose or a combination of a RAS-blocker a calcium channel blocker in low dose. If the target is not reached within 12 weeks additional drugs should be added.~Dyslipidemia: Patients with a CVD risk of 2-8% within 5 years should receive treatment with atorvastatin 10mg +ezetimib 10mg; CVD risk 8-20%, atorvastatin 20mg + ezetimib 10mg and CVD risk > 20% atorvastatin 40-80mg +ezetimib 10mg.